Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Marion Moos"'
Autor:
Jérôme Moreaux, Dirk Hose, Michel Jourdan, Thierry Reme, Michael Hundemer, Marion Moos, Nicolas Robert, Philippe Moine, John De Vos, Hartmut Goldschmidt, Bernard Klein
Publikováno v:
Haematologica, Vol 92, Iss 6 (2007)
Background and Objectives BAFF and APRIL stimulate the growth of multiple myeloma (MM) cells. BAFF and APRIL share two receptors – TACI and BCMA – and BAFF binds to a third receptor, BAFF-R. We previously reported that TACI gene expression is bim
Externí odkaz:
https://doaj.org/article/fe7a029f02a448a98a18f840a2b41935
Autor:
Marion Moos
Publikováno v:
unsere jugend. 72:146-155
Gute Heimerziehung gibt es, das steht auser Frage. Aber sie ist anspruchsvoll und steht immer wieder vor der Herausforderung, sich offen und flexibel zu gestalten, um den Bedarfen von Kindern, Jugendlichen und ihren Familien gerecht werden zu konnen.
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 134:1949-1952
Autor:
Sebastian Belle, Friedrich W. Cremer, Olaf Christensen, Maud Condomines, Dirk Hose, Bernard Klein, Marion Moos, Hartmut Goldschmidt, Alaviana D. Lupu, Christian Kleist, Anthony D. Ho, Michael Hundemer, Stefanie Schmidt, Peter Terness
Publikováno v:
Experimental Hematology
Experimental Hematology, Elsevier, 2006, 34 (4), pp.486-96. ⟨10.1016/j.exphem.2006.01.008⟩
Experimental Hematology, Elsevier, 2006, 34 (4), pp.486-96. ⟨10.1016/j.exphem.2006.01.008⟩
International audience; OBJECTIVE: The aim of this study was identification of human leukocyte antigen (HLA)-A2-restricted T-cell epitopes within the HM1.24 antigen as target for multiple myeloma (MM)-directed specific peptide-based immunotherapy. ME
Autor:
Marc S. Raab, Dirk Hose, Michaela Brough, Marion Moos, Friedrich W. Cremer, Claus R. Bartram, Hans Dieter Hager, Anke Moebus, Mutlu Kartal, Hartmut Goldschmidt, Frauke Bellos, Isabelle Buck, Jelena Bila, Anna Jauch
Publikováno v:
Cancer Genetics and Cytogenetics. 161:116-124
In multiple myeloma, additional copies of chromosome 11 material, reported to confer an unfavorable prognosis, have been found in 20–45% of patients. To assess the incidence and extent of chromosome 11 aberrations, we performed interphase fluoresce
Autor:
Thomas Luft, I. Breitkreutz, M. S. Raab, A. D. Ho, Sabine Gerull, Axel Benner, Martin Goerner, Friedrich W. Cremer, H. Goldschmidt, Marion Moos
Publikováno v:
Annals of Oncology. 16:611-617
Background: Non-myeloablative allogeneic stem cell transplantation followed by immunomodulatory therapies is considered a potentially curative approach in the treatment of multiple myeloma and most effective in a minimal residual disease setting. Pat
Autor:
Hartmut Goldschmidt, Friedrich W. Cremer, Ben Van Camp, Marion Moos, Jane F. Apperley, D. Samson, Kris Thielemans, Yasmina Bouko, Marleen Bakkus, Axel Benner
Publikováno v:
British Journal of Haematology. 126:665-674
High-dose therapy (HDT) and autologous transplantation prolongs remission duration and survival in multiple myeloma (MM), but relapse still occurs at a median of 2 years post-HDT. In order to investigate whether the number of residual tumour cells in
Publikováno v:
British Journal of Haematology. 123:646-653
Summary. This study evaluates the immunological effects in 21 patients with multiple myeloma (MM) following allogeneic stem cell transplantation with a non-myeloablative conditioning regimen. Patients were heavily pretreated, most of them having prog
Autor:
Lambros Kordelas, M Punzel, Marion Moos, R. M. Weber-Nordt, A. D. Ho, M Thalheimer, F Ustaoglu, Martin Görner, Thomas Luft, S Pfeiffer, H. Goldschmidt
Publikováno v:
Bone Marrow Transplantation. 29:621-624
Although reduced intensity conditioning (RIC) before allografting is associated with low treatment-related morbidity and mortality, graft-versus-host disease (GVHD) remains a significant complication of hematopoietic stem cell transplantation (HSCT).
Autor:
Marion Moos, M. Witzens, A. D. Ho, Friedrich W. Cremer, C Gemmel, H. Goldschmidt, Imbach U, Koniczek Kh, Gerhard Moldenhauer, Weis M
Publikováno v:
Annals of Hematology. 81:119-123
In multiple myeloma (MM), circulating malig- nant B cells are proposed as the proliferative compart- ment of the disease. In view of the close relationship be- tween multiple myeloma and primary plasma cell leuke- mia (PCL), an anti-CD20 antibody tre